Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05856526 · ClinicalTrials.gov registry record · Phase 2
A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT05856526 is a Phase 2 study that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 43 participants.
The verdict
NCT05856526, a Phase 2 study, was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
This study is open to people with a skin disease called Netherton syndrome (NS). People can join the study if they are 12 years or older. The purpose of this study is to find out whether a medicine called spesolimab helps people with NS. Participants are divided into a spesolimab and a placebo group. Placebo injections look like spesolimab injections but do not contain any medicine. Every participant has a 2 in 3 chance of being in the spesolimab group. In the beginning, participants get the study medicine as an injection into a vein. Afterwards, they get it as an injection under the skin every month. After 4 months, participants in the placebo group switch to spesolimab treatment. Participants are in the study for up to 3 years. During this time, they visit the study site up to 42 times. The doctors regularly check participants' NS symptoms. The results are compared between the groups to see whether spesolimab works. The doctors also regularly check participants' general health and take note of any unwanted effects.
Interventions
- DRUG Spesolimab - solution for infusion
- DRUG Placebo matching to spesolimab - solution for infusion
- DRUG Spesolimab - solution for injection
- DRUG Placebo matching to spesolimab - solution for injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2023-06-12 |
| Est. Completion | 2025-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05856526
The ClinicalTrials.gov registry entry for NCT05856526 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Spesolimab - solution for infusion is the first listed.
NCT05856526 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05856526 about?
NCT05856526 is a clinical study titled "A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome". This study is open to people with a skin disease called Netherton syndrome (NS). People can join the study if they are 12 years or older. The purpose of this study is to find out whether a medicine called spesolimab helps people with NS. Participants are divided into a spesolimab and a placebo grou...
What is the current status of trial NCT05856526?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2023-06-12. Estimated completion is 2025-07-31.
What interventions are being tested in trial NCT05856526?
The interventions under investigation include: Spesolimab - solution for infusion (DRUG), Placebo matching to spesolimab - solution for infusion (DRUG), Spesolimab - solution for injection (DRUG), Placebo matching to spesolimab - solution for injection (DRUG).
Who is sponsoring clinical trial NCT05856526?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.